Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 269

1.

[Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].

Matveeva OV, Kochneva GV, Zainutdinov SS, Ilyinskaya GV, Chumakov PM.

Mol Biol (Mosk). 2018 May-Jun;52(3):360-379. doi: 10.7868/S0026898418030023. Russian.

PMID:
29989571
2.

Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.

Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfeld C, Jäger D, von Kalle C, Ungerechts G.

Mol Ther Oncolytics. 2018 Apr 12;9:30-40. doi: 10.1016/j.omto.2018.04.002. eCollection 2018 Jun 29.

3.

An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.

Lal S, Carrera D, Phillips JJ, Weiss WA, Raffel C.

Neuro Oncol. 2018 Jun 14. doi: 10.1093/neuonc/noy089. [Epub ahead of print]

PMID:
29912438
4.

Oncolytic Viruses for Multiple Myeloma Therapy.

Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST.

Cancers (Basel). 2018 Jun 14;10(6). pii: E198. doi: 10.3390/cancers10060198. Review.

5.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy033. [Epub ahead of print]

PMID:
29788332
6.

Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading.

Xu C, Xia M, Meng G, Li C, Jiang A, Wei J.

Virol Sin. 2018 May 16. doi: 10.1007/s12250-018-0033-2. [Epub ahead of print]

PMID:
29767404
7.

The emerging role of oncolytic virus therapy against cancer.

Russell L, Peng KW.

Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

8.

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies.

Xu C, Goß AV, Dorneburg C, Debatin KM, Wei J, Beltinger C.

Oncolytic Virother. 2018 Apr 30;7:37-41. doi: 10.2147/OV.S150637. eCollection 2018.

9.

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A.

Oncotarget. 2018 Jan 12;9(16):12971-12981. doi: 10.18632/oncotarget.24191. eCollection 2018 Feb 27.

10.

Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.

Son HA, Zhang L, Cuong BK, Van Tong H, Cuong LD, Hang NT, Nhung HTM, Yamamoto N, Toan NL.

Cancer Invest. 2018 Feb 7;36(2):106-117. doi: 10.1080/07357907.2018.1434539. Epub 2018 Feb 27.

PMID:
29485292
11.

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.

Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE.

Clin Cancer Res. 2018 May 1;24(9):2128-2137. doi: 10.1158/1078-0432.CCR-17-2651. Epub 2018 Feb 6.

PMID:
29437789
12.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

PMID:
29399408
13.

Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus.

Lal S, Raffel C.

Mol Ther Oncolytics. 2017 Sep 29;7:57-66. doi: 10.1016/j.omto.2017.09.005. eCollection 2017 Dec 15.

14.

Measles virus: Background and oncolytic virotherapy.

Bhattacharjee S, Yadava PK.

Biochem Biophys Rep. 2018 Jan 2;13:58-62. doi: 10.1016/j.bbrep.2017.12.004. eCollection 2018 Mar. Review.

15.

High titer oncolytic measles virus production process by integration of dielectric spectroscopy as online monitoring system.

Grein TA, Loewe D, Dieken H, Salzig D, Weidner T, Czermak P.

Biotechnol Bioeng. 2018 May;115(5):1186-1194. doi: 10.1002/bit.26538. Epub 2018 Feb 4.

PMID:
29288575
16.

Measles Vaccine.

Griffin DE.

Viral Immunol. 2018 Mar;31(2):86-95. doi: 10.1089/vim.2017.0143. Epub 2017 Dec 19.

PMID:
29256824
17.

Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD.

Sci Rep. 2017 Dec 4;7(1):16892. doi: 10.1038/s41598-017-16928-8.

18.

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma.

Jacobson BA, Sadiq AA, Tang S, Jay-Dixon J, Patel MR, Drees J, Sorenson BS, Russell SJ, Kratzke RA.

Oncotarget. 2017 Jun 27;8(38):63096-63109. doi: 10.18632/oncotarget.18656. eCollection 2017 Sep 8.

19.

Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Ha MN, Delpeut S, Noyce RS, Sisson G, Black KM, Lin LT, Bilimoria D, Plemper RK, Privé GG, Richardson CD.

J Virol. 2017 Nov 14;91(23). pii: e01026-17. doi: 10.1128/JVI.01026-17. Print 2017 Dec 1.

20.

Oncolytic Viral Therapy for Mesothelioma.

Pease DF, Kratzke RA.

Front Oncol. 2017 Aug 24;7:179. doi: 10.3389/fonc.2017.00179. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center